Early initiation of prostanoid therapy yields favorable outcome in children with PAH

In children with pulmonary arterial hypertension, early initiation of IV or subcutaneous parenteral prostanoid therapy, higher doses of therapy and when combined with additional PAH therapy were associated with favorable outcomes.
“Currently, IV/subcutaneous prostanoids are not formally approved for children by the Europeans Medicines Agency or the U.S. FDA, but generally used as an accepted therapy in pediatric PAH,” Johannes M. Douwes, MD, PhD, from the department of pediatric cardiology at the Center for Congenital Heart Diseases at Beatrix Children’s Hospital in

In children with pulmonary arterial hypertension, early initiation of IV or subcutaneous parenteral prostanoid therapy, higher doses of therapy and when combined with additional PAH therapy were associated with favorable outcomes.
“Currently, IV/subcutaneous prostanoids are not formally approved for children by the Europeans Medicines Agency or the U.S. FDA, but generally used as an accepted therapy in pediatric PAH,” Johannes M. Douwes, MD, PhD, from the department of pediatric cardiology at the Center for Congenital Heart Diseases at Beatrix Children’s Hospital in